(Q37633540)

21 August 2017

1 reference

title

Trastuzumab for gastric cancer (English)

1 reference

21 August 2017

1 reference

Judith Meza-Junco

1

1 reference

21 August 2017

Heather-Jane Au

series ordinal

2

1 reference

21 August 2017

Michael B Sawyer

series ordinal

3

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

Expert Opinion on Biological Therapy

21 August 2017

1 reference

21 August 2017

9

1 reference

21 August 2017

12

1 reference

21 August 2017

1543-1551

1 reference

Gastric cancer: pathogenesis, screening, and treatment

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Epidemiology of gastric cancer in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Advances in the treatment of patients with gastric adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

The treatment of advanced gastric cancer: current strategies and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Review of second-line chemotherapy for advanced gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Chemotherapy for metastatic gastric cancer in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Gastric cancer in the era of molecularly targeted agents: current drug development strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Chemotherapy for metastatic gastric cancer: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Current perspective - trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Cardiac dysfunction in the trastuzumab clinical trials experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

HER-2 amplification is highly homogenous in gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903439702

10.1517/14712590903439702

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference